Abstract
CP is mainly activated by C1q reacting with antibodies bound to antigen [1, 2] and also by other agents, such as C-reactive protein (CRP) [3, 4] , SIGN-R1, a lectin that captures microbial polysaccharides in the spleen [5] , and phosphatidylserine being important for efficient removal of apoptotic cells [6] .
LP is mainly activated by mannose-binding lectin (MBL) interacting with carbohydrate structures on microbial surfaces and by ficolins with different fine carbohydrate binding specificity [7] [8] [9] [10] [11] .
MBL reacts in particular with terminal mannose residues but also with other sugars, like N-acetyl-D-glucosamine, while ficolin 2 and 3 are pattern recognition molecules for acetyl groups.
The alternative pathway (AP) is slowly activated spontaneously by hydrolysis of the internal C3 thioester bond [12] [13] [14] and further triggered by contact with various proteins, lipids and carbohydrate structures on microorganisms and other foreign surfaces [1, 15] .
Activation of the initial pathways results in formation of C5 convertases splitting C5. C5a is a potent anaphylatoxin. C5b induces assembly of the later components into the terminal C5b-9 complement complex, TCC [1, 2] . The terminal pathway is biologically highly potent and responsible for much of the inflammatory reaction induced by initial activation, particularly through the C5a receptor. A reduced AP amplification will thus in most cases substantially attenuate the effects of terminal pathway activation, although a direct C5 activation pathway without prior C3 involvement was recently postulated [16] . [1, 2, 17] , in particular in ischaemia/reperfusion (I/R) injury [18, 19] . Clinical evidence pointed to complement and immune complexes as critical players in mediating reperfusion injury [20] . Intestinal I/R injury could also be initiated by clonally specific natural IgM antibodies [21] . [22, 23] [44] . [45] . A common feature for any initial complement activation is AP amplification. Initial activation of both CP and LP generates a common C3 convertase, C4b2a, forming C3b, which is essential in starting up the amplification loop providing a rational explanation for the common AP amplification (Fig. 1) .
The complement system with a central position in acquired as well as innate immunity mediates a variety of effector functions. During the past decades, it has become evident that it is also an important mediator of tissue damage in disease

Results in early studies of C3 and C4 knockout (Ϫ/Ϫ) mice suggested an important role of CP or LP in inducing complement activation during skeletal muscle and intestinal I/R injury
The relative importance of CP and LP in I/R injury may thus vary in different models. The basis for this variation remains to be shown, although initiation of the reaction by the clonal IgM antibody is a common feature. Variation in the content of the reactive epitope in different tissues may be an important feature to explain that apparently different mechanisms of complement activation occur in different organs. There are indications that the I/R injury in the heart is initiated by MBL and the LP [39], whereas renal I/R injury might be due to loss of regulators of the AP in the tubuli
Although [49, 50] , arthritis in mice triggered by immune complex deposition [51] , anti-phospholipid antibody-mediated foetal injury [31, 52, 53] and collagen antibody-induced arthritis in mice [54] [57] . Thus, initial triggering of CP, the effect of which is largely determined by AP amplification, also appears to be a central feature in these circumstances. [58] . [61, 62] . Properdin associates with C3bBb forming a more stable C3bBbProperdin (C3bBbP) complex [63, 64] [66] and 'provided evidence that properdin:target complexes directed antibody-independent complement activation ' [27] . Reaction between properdin and various bacterial polysaccharides was also reported by Pillemer et al. [67] . The findings were difficult to reproduce, criticized, and with Pillemer's death [68] [69] [70] properdin was largely dismissed by the scientific community. The properdin system was reborn as the AP more than 20 years later [27, 69] [73, 74] . [75] [76] [77] [78] [79] . A role for fH in surface protection of endothelial cells has been proposed as a pathophysiologic mechanism which may explain the predisposition of diseases related to genetic variations in the protein [80] . Furthermore, genetic variants of other complement regulators controlling the AP activation (MCP, fI and fB, the latter by 'gain of function') display similar disease predispositions [81, 82] . Based on the role of AP in a number of serious diseases [83] , therapeutic strategies for interference with AP have been proposed [84] .
Experimental data indicate that anti-neutrophil cytoplasmic autoantibodies (ANCAs) induce glomerulonephritis and vasculitis through another mechanism. After injection of IgG anti-myeloperoxidase (MPO-ANCA), C4 -/-mice developed disease comparable to wild-type mice while fB -/-mice developed no disease, indicating a primary role of AP in induction of the disease. Incubation of MPO-ANCA or anti-myeloperoxidase 3 ANCA with human neutrophils stimulated the cells resulting in release of factors activating AP, citation: 'thus initiating an inflammatory amplification loop that mediates the severe necrotizing inflammation of ANCA disease'
Mechanisms of amplification
Initial activation of CP and LP generates a common C3 convertase, C4b2a, splitting C3 into C3a and C3b. Upon formation of C3b the amplification loop of AP is induced on the activating surface and/or in the fluid phase. Different mechanisms of amplification in the fluid phase and on cell surfaces are discussed in more detail by Lutz and Jelezarova [59] and visually illustrated in Figures 1 and 2 in their paper. In the fluid phase, amplification is maintained primarily by C3b2-IgG complexes. These complexes bind properdin bivalently and have a half-life longer than free C3b since both C3b molecules are partially protected from inactivation by fH and fI, promoting AP amplification. On cell surfaces nascent C3b binds covalently with the thioester bond to surface components forming clusters recruiting fB, fD and properdin resulting in additional convertase activity and amplification. A common feature of the experimental models discussed above is the central importance of AP amplification. In addition, clinical evidence underlines the prominent role of complement in the pathogenesis of numerous inflammatory diseases. The list of such conditions is rapidly growing, including immune complex diseases such as rheumatoid arthritis and systemic lupus erythematosus, I/R injury locally manifested as infarctions or systemically as a post-ischaemic inflammatory syndrome, systemic inflammatory response syndrome and acute respiratory distress syndrome, renal diseases, inflammatory and degenerative diseases in the nervous system, transplant rejection and inflammatory complications after cardiopulmonary bypass and haemodialysis. In principle, when inflammation is involved in the pathogene
It has become evident that not only fH deficiency, but also genetic variants and polymorphisms predispose to several other serious diseases like atypical haemolytic uremic syndrome and age-related macular degeneration
C2 bypass in CP and LP
The complement system is a typical cascade system with a strict order of activation and amplification at specific sites. In genetic deficiencies of individual components, bypass mechanisms have been identified, like 'C2 bypass' in C2 deficiency.
Basic observations on CP C2 deficiency were made in guinea pigs [85] . [86] . [88] [89] [90] . Deficiency of one of the terminal complement components leads to inadequate TCC formation and increased risk of meningococcal infection, estimated up to 6000-fold [88, 90] . Interestingly, most of these infections are caused by relatively rare serogroups and run a mild course [91] . In deficiencies of earlier components, C3b-mediated clearance of bacteria is missing and a more severe course may be expected, as often observed in properdin deficiency [87, 92] [90, 102] .
Properdin deficiency
We demonstrated a strong correlation between the degree of complement activation at hospital entry and the subsequent course in patients with systemic meningococcal disease [103] . Here, six of seven patients with TCC above a certain cut-off at admittance died during the course whereas only one of 32 of those with TCC below this value died (P < 0.0001). Using pathway-specific assays, we later showed that the overwhelming complement activation seen in those with fulminant, lethal septicaemia, was due to an uncontrolled AP amplification [104] .
In experimental models of gram-negative sepsis, it has been clearly demonstrated, using specific complement inhibitors, that complement activation is of essential importance in the development of septic shock [105] [107, 108] . LPS is known to activate complement, but large doses are needed compared to the trace amounts sufficient for cytokine production [109] . In fact, we also showed, using LPS-deficient and -sufficient Neisseria meningtidis strains, that membrane LPS plays a minor role in activating complement by the bacteria, in contrast to synthesis of cytokines [110] . Thus [111] , C1q modulates LPS/TLR-induced cytokine production [112] and MBL enhances TLR-2 and TLR-6 signalling from the phagosome [113] .
In recent studies of an Eschericia coli induced inflammatory response in human whole blood, combined inhibition of complement and CD14 completely abrogated up-regulation of CD11b, phagocytosis and oxidative burst, whereas inhibition of each of the systems abrogated the response only partially or marginally [109] . We suggest that combined inhibition of complement and CD14 should be further explored as a treatment regimen to reduce the overwhelming damaging inflammatory response during sepsis [114] . 
Concluding remarks
